Tenosynovial giant cell tumor (TGCT) is a locally aggressive neoplasm affecting the synovium of joints, tendon sheaths, and bursae1. TGCT has historically been known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS)1,2, and can be categorized as either nodular (localized)-type or diffuse-type1.
For most patients with nodular-type TGCT, surgery can be effective3, with post-surgical recurrence rates varying based on the anatomical location of the tumor1,4. For diffuse-type TGCT cases, surgical technique did not influence functional outcomes in patients with diffuse-type TGCT5 and post-surgical recurrence rates can be as high as 72%6.
What is TGCT?
MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience with Vimseltinib
MOVE is an observational study (NCT07075471) with the goal of better understanding real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT.
- To learn more about the registry, visit TGCTRegistry.com.
References
1) Stacchiotti S, et al. Cancer Treat Rev. 2023;112:102491.
2) Mastboom MJL, et al. Acta Orthop. 2017;88(6):688-94.
3) Gouin F, et al. Orthop Traumatol Surg Res. 2017;103(suppl 1):S91-7.
4) Mastboom MJL, et al. Interact J Med Res. 2018;7(1):e4.
5) Mastboom MJL, et al. Lancet Oncol. 2019;20:877-86.
6) Stern S, et al. Presented at: CTOS Annual Meeting 2024; November 16, 2024; San Diego, CA.